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Ruthenium complexes as antimicrobial agents
Fangfei Li,a J. Grant Collins*a and F. Richard Keene*bcd
One of the major advances in medical science has been the development of antimicrobials; however, a
consequence of their widespread use has been the emergence of drug-resistant populations of
microorganisms. There is clearly a need for the development of new antimicrobials – but more importantly,
there is the need for the development of new classes of antimicrobials, rather than drugs based upon analogues
of known scaffolds. Due to the success of the platinum anticancer agents, there has been considerable interest
in the development of therapeutic agents based upon other transition metals – and in particular ruthenium(II/III)
complexes, due to their well known interaction with DNA. There have been many studies of the anticancer
properties and cellular localisation of a range of ruthenium complexes in eukaryotic cells over the last
decade. However, only very recently has there been significant interest in their antimicrobial properties.
This review highlights the types of ruthenium complexes that have exhibited significant antimicrobial
activity and discusses the relationship between chemical structure and biological processing – including
site(s) of intracellular accumulation – of the ruthenium complexes in both bacterial and eukaryotic cells.
1. Microbial infection
The struggle to control bacterial and other microbial infectious
diseases has persisted throughout human history. Over centuries,
epidemics such as cholera and plague (‘bubonic plague’ in lymph
nodes, ‘septicemic plague’ in blood vessels, and ‘pneumonic
plague’ in lungs) have at times been prevalent and widespread,
occasionally resulting in dramatic regional population decreases.1
Pneumonia – described as ‘‘the captain of the men of death’’ in
the 19th Century – today still infects 7% of the world’s population
with four million deaths reported every year.2 Tuberculosis (TB) is
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another common and often deadly infectious disease in humans,
with more than 1.5 million deaths per year worldwide.3
One of the major advances in medical science over the last
century has been the development of antimicrobials.4 However, a
consequence of their widespread use has been the emergence of
drug-resistant populations of microorganisms. Infection by such
drug-resistant pathogens has become an important cause of
morbidity and mortality worldwide once again: in a recent
update from the Infectious Diseases Society of America,5
Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae,
Acinetobacter baumanni, Pseudomonas aeruginosa and Enterobacter
species were identified as the pathogens of most current concern.
In particular, methicillin-resistant S. aureus (MRSA, colloquially
known as Golden Staph), vancomycin-resistant Enterococcus
(VRE) and fluoroquinolone-resistant P. aeruginosa show rapidly
increasing incidence of infection, with treatment failure leading
to high mortality rates.5 Furthermore, and despite considerable
research, Mycobacterium tuberculosis (the causative agent of the
disease tuberculosis) and malaria (particularly caused by the
eukaryotic Plasmodium falciparum-induced infection) remain
major causes of concern, due in part to persistent antimicrobial
resistance, leading to treatment failure and high mortality rates.
Although 90% of tuberculosis is asymptomatic, it is estimated
that 33% of the world population is infected with the organism:3
while the antibiotic rifampicin and the antibacterial isoniazid can
be used to treat TB, there is a worrying increase in the emergence
of M. tuberculosis strains resistant to these drugs (MDR-TB), with
some strains resistant to all known treatments (XDR-TB). In the
case of malaria, it has been estimated that the malaria parasite
infects 500 million people annually, particularly in sub-Saharan
Africa, where ‘‘one child dies every 30 seconds from infection’’.6
There is clearly a need for the development of new anti-
microbials; but more importantly, there is the need for the
development of new classes of antimicrobials, rather than drugs
necessarily based upon analogues of known scaffolds.
2. Cellular structure of bacteria
Bacteria are a group of microscopic and single-celled prokar-
yotic microorganisms. In general, the cocci range from 0.5 to
1.0 mm in diameter, while for bacilli, spirilla and other non-
spherical species the width ranges from 0.2 to 2.0 mm and the
length ranges from 1 to 20 mm.7,8 As prokaryotes, bacteria have
a characteristic cellular organisation (Fig. 1) which is distinct
from the structure of eukaryotes.
2.1 Genetic material
The genetic information is carried in the bacterial chromosome,
which is a single circular double-stranded DNAmolecule. Bacterial
chromosomal DNA is supercoiled in a non-membrane bound
structure known as the nucleoid.9,10 The structural configuration
of the DNA is controlled by two enzymes, DNA gyrase and
topoisomerase I, which can introduce or relax the supercoils.9
Besides chromosomal DNA, a variable number of small
circular self-replicating double-stranded DNA molecules called
plasmids can also be present in the cytoplasm and carry
supplementary information.10,11
2.2 Ribosomes
The only organelle found in bacteria is the ribosome, the site of
protein synthesis. Bacterial ribosomes are composed of ribosomal
RNA and proteins, with the functional organelle containing
two parts, the 30S and 50S subunits (S is the abbreviation of
the Svedberg unit, a measure of the rate of sedimentation in
centrifugation).12,13 In rapidly growing bacterial cells, most of the
ribosomes appear in the form of polysomes, where several ribo-
somes carry out translation on a single messenger RNA strand.14
2.3 Cytoplasmic membrane
Like all cells, the bacterial internal structures are surrounded
and protected by a cytoplasmic membrane. The cytoplasmic
membrane of bacteria consists of a phospholipid bilayer and is
similar to the cell membrane of eukaryotes except for the wider
Fig. 1 The structure of a typical bacterial cell (a) and an electron microscopy
photo of a bacterial cell (b). [Image taken from G. J. Tortora, B. R. Funke
and C. L. Case, Microbiology: An Introduction, Pearson Education, Inc.,
San Francisco, 8th edn, 2004].
F. Richard Keene
Richard Keene graduated as a PhD
from the University of Adelaide in
1973. He was appointed to the
staff of James Cook University
(Townsville) in 1978, from where
he retired in 2012 as a
Distinguished Professor. His recent
research interests have centred
primarily on the stereochemistry of
metallosupramolecular assemblies
and its effect on their physical
properties – in particular intra-
molecular electron transfer, and
the interaction with biological
molecules such as nucleic acids. This latter interest has extended over
the last decade to the efficacy of oligonuclear metal complexes as
anticancer and antimicrobial agents. Richard was awarded a DSc by
the University of Adelaide in 1998, and was conferred as an Emeritus
Professor on his retirement from JCU. He is currently an Honorary
Visiting Research Fellow at the University of Adelaide.
Review Article Chem Soc Rev
This journal is©The Royal Society of Chemistry 2015 Chem. Soc. Rev., 2015, 44, 2529--2542 | 2531
variety of fatty acids, a higher content of negatively-charged
phospholipids and the absence of sterols within the membrane.15
As a selective permeability barrier, the bacterial cytoplasmic
membrane regulates the exchange of substances between the
cytoplasm and the outer environment. Many important cellular
bio-processes also take place in the cytoplasmic membrane,
such as energy production, protein secretion and chromosome
segregation.16,17 In addition, under different environmental
stresses, the fluidity of the membrane can be modulated by
varying the proportions and types of saturated and unsaturated
fatty acids in the phospholipids.18
2.4 Cell wall
Bacteria must survive in some extreme conditions in which
eukaryotes are not able to do so. Thus a rigid cell wall outside
the cell membrane is essential for the protection of the cell from
osmotic pressure, chemical or enzymatic lysis and mechanical
damage.17 Due to the distinct structure of the cell wall, bacteria are
classified into two groups by the Gram staining procedure – Gram
positive and Gram negative bacteria. The cell wall of Gram positive
bacteria (which retain the purple colour of the Crystal Violet stain
after the procedure) is composed of a thick layer of peptidoglycan
with a group of inlaid molecules called teichoic acids.17,19 In
contrast, in the absence of teichoic acid molecules, the Gram
negative cell wall consists of a thin layer of peptidoglycan but it is
covered by an outer membrane.10,17,19 Besides phospholipids, the
outer membrane contains LPS (lipopolysaccharide), a unique
structure on the surface directed towards the external environ-
ment. LPS is a highly negatively-charged amphiphilic molecule
and comprises lipid A, the core and the O antigen.20 It is stabilised
by divalent cations such as calcium and magnesium. The outer
membrane, with the LPS, greatly decreases the permeability to
antibacterials and is regarded as one of the major mechanisms of
resistance to drugs for many pathogenic Gram negative bacteria.21
Bacteria may also have an additional capsule (normally covered
with a slimy layer) lying outside of the cell wall for further
protection against phagocytosis by host cells. Some other external
structures such as flagella, fimbriae and pili may also be present to
aid the movement of a bacterium or attachment to a surface.10,15
2.5 Comparison with eukaryotes
The differences in the cellular structure between bacteria and
eukaryotes are briefly summarised in Table 1. These differences
are the basis for the selective targeting of many antibacterial drugs.
It is worth mentioning that from an evolutionary perspective,
bacteria are believed to be the origin of the mitochondria in
eukaryotic cells.22 Amitochondrion is of similar size to a bacterium,
and the mitochondrial ribosome structure is closer to prokaryotes
than the ribosomes found in the cytoplasm of eukaryotes. Most
importantly, it has been reported that the mitochondrial genomes
are evolved from a bacterial ancestor.22
3. Antibacterials
Since the discovery of penicillin, the first antibiotic, a great
number of compounds have been subsequently developed and
clinically used for the treatment of infections by bacteria and
other pathogens. However, not long after the beginning of the
‘antibiotic era’, another severe challenge arose – the emergence
of bacteria resistant to existing antibiotics as well as other
antimicrobials. The pipeline of new antimicrobials is now a
particular challenge, and thus there is an urgent need for the
development of targets, particularly those with novel structures.
3.1 Mechanisms of action of antibacterials
Existing antibacterials are classified into four major groups
based upon their intracellular target and their mechanism of
action (see Fig. 2).
(1) Cell wall synthesis inhibition; e.g. penicillin and deriva-
tives, cephalosporins, carbapenems and glycopeptides.23–25
These compounds are more effective against infection by Gram
positive bacteria.
(2) Cell membrane disruption; e.g. the family of polycationic
peptide antibiotics called polymyxins.26–28 Polymyxins are
used in the treatment of infection by Gram negative bacteria,
and are considered a last-line therapy against Gram negative
‘superbugs’.27
(3) Nucleic acid synthesis inhibition; e.g. quinolones, rifampicin
and sulphonamides.29–32 The fluoroquinolones are one of
a few examples of a broad-spectrum synthetic antimicrobial in
clinical use.29
(4) Protein synthesis inhibition; e.g. tetracycline, amino-
glycosides, chloramphenicol and macrolides.33–35 A large propor-
tion of clinically-used antibacterials inhibit protein synthesis by
targeting the ribosomal-RNA rich surfaces of ribosomes, and in
some cases can be effective against tuberculosis.35
Table 1 The structural comparison between bacteria and eukaryotes
Bacteria Eukaryotes
Cell size Commonly 1–10 mm Commonly 10–100 mm
Cell type Usually unicellular Usually multicellular
Genetic material A non-membrane bound single circular
DNA molecule; plasmids
A membrane-bound nucleus is present and
contains more than one chromosome
Ribosome 70S, with 30S and 50S subunits 80S, with 40S and 60S subunits
Other organelles Absent Mitochondria or chloroplasts, endoplasmic reticulum,
golgi apparatus, cytoskeleton, lysosomes
Cytoplasmic membrane Wider variety of fatty acids, higher content of
negatively-charged phospholipids, absence of sterols
More uniformed distribution of fatty acids, high
percentage of neutral phospholipids, presence of sterols
Cell wall Present Absent
Outer cellular structures Capsule, flagella, fimbriae, pili Absent
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3.2 Mechanisms of resistance to antibacterials
The prevalence of drug-resistant bacterial infections makes it
crucial to understand the mechanisms of drug resistance
developed by microorganisms. Antibacterial resistance is
manifested through a variety of biochemical processes that
are genetically controlled, developed by either mutation of
intrinsic cellular genes or by the acquisition of resistance
genes from the other bacteria.36 The biochemical mechanisms
of resistance involves drug inactivation or modification by
enzymes, target modification, target repair, target overproduction,
immunity and bypass, efflux pumps, increased impermeability
and tolerance, biofilm formation and other unrecognised
mechanisms.36–38 The mechanisms of resistance to the currently-
used antibiotics are summarised in Table 2.
4. Metal-based antimicrobial agents
Metal- and metalloid-based drugs play an important part in
the history of medicinal chemistry. Salvarsan (Fig. 3a–c), an
organoarsenic compound for syphilis treatment developed
by Paul Ehrlich and his co-workers in the 1900s, was the first
successful application of metalloid complexes in chemotherapy.39
After half a century, another breakthrough – the discovery
of the anti-tumour properties of cis-diamminedichlorido-
platinum(II) (cisplatin, Fig. 3d) and its derivatives – paved the
way for the subsequent development of metal-based chemothe-
rapeutic agents.40 A variety of metal complexes with different
metal centres (mainly transition metal elements) and ligands of
diverse structures were synthesised and studied for their bio-
logical activity. Because of the range of coordination geome-
tries, metal complexes provide more stereochemical variability
than is possible in organic molecules and often introduce new
elements of chirality which may be important for biological
molecule recognition and interaction. The metal complexes can
also be highly positively-charged: sincemany biological structures –
such as DNA and RNA, several types of phospholipids, and some
regions of proteins – are negatively charged, for electrostatic
Fig. 2 Classification of antibiotics by mechanism of action. [Image by
Kendrick Johnson: Creative Commons Attribution-Share Alike 3.0
Unported license].
Table 2 Mechanism of resistance to currently used antibiotics and
antibacterials36–38
Antibiotic Mechanism of resistance
b-Lactams Antibacterial inactivation (b-lactamase)
Modification of penicillin-binding proteins
(PBPs)
Efflux
Impermeability
Glycopeptides Target modification (gene van A)
Polymyxins Modification of target
PhoP–PhoQ system
Quinolones Alteration of target enzymes
Impermeability
Rifampicin Target modification (gene rpoB)
Sulfonamides Target modification (genes sul1 and sul2)
Chloramphenicol Antibacterial inactivation (acetyltransferase)
Active efflux
Impermeability
Tetracyclines Efflux
Ribosome protection
Modification of the antibiotic
Aminoglycosides Impermeability
Enzymatic modification (AMEs)
Fig. 3 The chemical structures of several metal/metalloid-based therapeutic
agents. (a–c) Salvarsan – the initially proposed structure (a), although it has
been shown to be a mixture of (b) and (c); cisplatin (d); NAMI-A (e); and
KP1019 (f).
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reasons the positive charge of metal complexes could aid the
binding with intracellular targets. It has been reported that a range
of transition metal complexes (including Ag, Au, Cu, Fe, Ir, Pt, Rh,
Ru, Ti, etc.) bind DNA and RNA with a relatively high affinity
andmany of them have shown anticancer activity.41,42 Furthermore,
a number of transition metal complexes display antimicrobial
activity. For example, silver nitrate and silver(I) sulfazine are
used clinically for treatment for ophthalmia neonatorum and
severe burns infections, respectively,43 and silver complexes
with oxygen donor ligands exhibit a wide-spectrum antimicrobial
activity;44 a series of gold(I) anti-arthritic drugs were shown to
exhibit inhibition against Pseudomonas putida;45 Richards et al.
found that an iron triple-helicate complex binds bacterial
chromosomal DNA and is bactericidal against E. coli and
Bacillus subtilis with a moderate minimum inhibitory concen-
tration (MIC).46 Ng et al. demonstrated that some copper(II)- and
platinum(II)-based metallointercalator complexes could exhibit
good antimicrobial activity against S. aureus.47 Interestingly,
some of the copper complexes substantially permeabilised the
bacterial membrane while others had little effect.47 Furthermore, a
range of metal complexes (Mn, Fe, Co, Ni, Cu and Zn) containing
Schiff base ligands have shown modest antimicrobial activity
against bacteria and fungi.48 There is also a group of metal
complexes containing existing antibacterials as ligands:49,50
compared to their parent organic antibacterial, the metalloanti-
bacterial normally show enhanced antimicrobial activity, especially
against drug-resistant bacterial strains.49–51
4.1 Ruthenium-based antimicrobial agents
Among the transition metal complexes, ruthenium-based com-
plexes have been widely studied and some have displayed
significant biological activity.52–63 This can be due to their ability
to strongly bind nucleic acids and proteins, ligand exchange
kinetics similar to those of their platinum counterparts, the
prevalence of two main oxidation states (II and III) and the iron-
mimicking property when bound to biological molecules.52–58
In addition, both the commonly accessible oxidation states of
ruthenium are octahedral and relatively inert, the synthetic
chemistry is very well established (including stereochemical
control), and the photophysical properties of many ruthenium(II)
complexes facilitate confocal microscopy and flow cytometry
studies of cellular accumulation and localisation.57,58 Over the
last decade their therapeutic potential as anticancer and anti-
microbial agents has been demonstrated.59–63
Nucleic acids are generally believed to be a target for many
metal-based drugs.64 Consequently, there have been many
studies of the interactions of ruthenium complexes with DNA
and RNA.53–58,64–67 Complexes with labile ligands (such as
KP1019, [Ru(terpy)(bpy)Cl]+ {terpy = 2,20:60,200-terpyridine} and
organometallic arene complexes) can bind DNA coordinatively,
predominantly at guanine residues.64,66 Through the addition
of extra functionality (e.g. extended arene rings), these coordi-
nating complexes can also bind DNA by hydrogen bonding and
hydrophobic interactions.64 Kinetically inert ruthenium com-
plexes {e.g. tris(bidentate) species containing polypyridyl
ligands} can bind reversibly to DNA and RNA by intercalation
or through association in either the major or minor groove.53–58,65,67
In addition to binding general duplex structures, inert ruthenium
complexes have been designed that specifically bind non-
duplex structures, such as mismatches, bulge sites, hairpins
and quadruplexes.57,58 The tailoring of ruthenium complexes to
specific nucleic acid sequences and structures is likely to become
more important as the biological significance of non-canonical
structures is determined.
Although less well explored, the structural properties of metal
complexes that allow strong interactions with nucleic acids
also provide a basis for targeting proteins and enzymes.68,69
Inert polypyridyl ruthenium complexes and ruthenium–arene
complexes have already been shown to bind and inhibit enzymes
such as acetylcholinesterase and protein kinases.68–70 For example,
the Meggers group have demonstrated that bulky pyridocarbazole
ruthenium complexes can inhibit the activity of p21-activated
kinase 1, which is implicated in tumourgenesis and metastasis,
at nanomolar concentrations.70 As outlined in recent reviews by
Meggers and Pandey and co-workers,68,69 metal complexes
(particularly octahedral complexes) have a number of features
that maymake themmore suitable than purely organic compounds
for the development as enzyme inhibitors. Although no example of
a ruthenium complex inhibiting a specific enzyme in live
bacteria has been reported to the best of our knowledge, it is
likely that proteins and enzymes will become important future
targets for the development of ruthenium complexes as anti-
microbial agents.
4.1.1 Inert polypyridylruthenium(II) complexes. Recently,
there has been a growing interest in the biological properties
of kinetically inert polypyridylruthenium(II) complexes.53–58
These ruthenium complexes are octahedral and reversibly
interact with important biological molecules, including DNA,
RNA and proteins. Rather than forming covalent bonds, inert
polypyridylruthenium(II) complexes can interact with DNA and
RNA reversibly via groove binding or intercalation, aided by
electrostatic attraction. Reversible binding may produce different
biological responses – both in terms of activity and toxicity – to
that observed for ruthenium complexes that covalently bind
their biological target. In addition, many of the polypyridyl-
ruthenium(II) complexes are chiral and can consequently
exhibit enantiomeric differences in their binding to chiral
biological receptors.
4.1.1.1 Mononuclear complexes. Over 60 years ago, Dwyer and
co-workers first investigated the biological activity of polypyridyl
metal complexes.59,71,72 The complexes they studied were mono-
nuclear tris(bidentate) inert metal complexes with ligands such as
1,10-phenanthroline and its derivatives (e.g. 3,5,6,8-tetramethyl-
1,10-phenanthroline and 5-nitro-1,10-phenanthroline) and 2,20-
bipyridine and its derivatives, coordinated predominantly to ruthe-
nium or iron. The antibacterial activities of these complexes were
determined against Gram positive, Gram negative and acid-fast
bacteria.59 [Ru(phen)3]
2+ (Fig. 4a) was shown to be inactive against
all the bacterial strains. However, the introduction of methyl group
substituents on the phenanthroline ligands (Fig. 4b) dramatically
increased the activity against all bacteria – especially Gram positive
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bacteria and Mycobacterium tuberculosis – indicating the impor-
tance of lipophilicity on antibacterial activity. The substitution of
nitro groups also significantly improved the anti-MTB activity. The
ruthenium(II) complexes exhibited better activity than quaternary
ammonium salts with a lower charge, and cobalt(III) complexes
with a higher charge, suggesting the importance of the charge and
lipophilicity of the metal complex. Interestingly, they also demon-
strated that the bacteria did not easily develop resistance to this
class of compound. For example, after sub-culturing Staphylococcus
pyogenes var. Phillips (a highly virulent bacterial strain) twenty-five
times at 48 hour intervals in the presence of the metal complex,
the bacteria only showed a two-fold increase in resistance to
[Ru(Me4phen)2(acac)]
+ (where acac = acetylacetonato; Fig. 4c).
Alternatively, there was a 10 000-fold decrease in the activity of
the antibiotic control penicillin.59 Moreover, in vivo bacterial
infection treatment studies with mice or guinea-pigs were also
conducted. Finally, it was proposed that this class of complexes
were suitable for topical application for surface infection treat-
ment rather than injection routes due to the rapid clearance
from the blood stream after administration.59,72
Although promising results were published, the mononuclear
polypyridyl metal complexes were not further developed as thera-
peutic agents. This may have been due to the growing interest in
their DNA binding ability, or perhaps because of the large number
of antibiotics in the pipeline in the 1960s and the vastly lower
incidence of drug-resistance at that time. However, recently
there has been renewed interest in the antimicrobial activity of
polypyridylruthenium(II) complexes. Aldrich-Wright and co-workers
reported mononuclear polypyridylruthenium(II) complexes that
could bind DNA by intercalation and exhibited significant
bactericidal activity against B. subtilis and S. aureus strains,
including several methicillin-resistant strains.63 Against the
Gram positive strains, some of the complexes exhibited MICs
as low as 2 mg ml1; however, they were inactive against Gram
negative bacteria. In addition, the treatment with the most active
compound, [Ru(2,9-Me2phen)2(dppz)]
2+ (Fig. 4d), increased the
survival population of Caenorhabditis elegans that were infected
with S. aureus, indicating the relatively lower toxicity against
eukaryotic systems.63 Satyanarayana and co-workers also found
that a range of mononuclear ruthenium complexes that contained
derivatives of either the dppz ligand or 2-phenyl-imidazo-1,10-
phenanthroline ligands had moderate activity.73 By contrast,
[Ru(L)2bdppz]
2+ {where L = 2,20-bipyridine or 1,10-phenanthro-
line and bdppz = 9a,13a-dihydro-4,5,9,14-tetraaza-benzotri-
phenylene-11-yl)-phenyl-methanone} only showed significant
antimicrobial activity at 1500 mg ml1 against S. aureus and
E. coli, despite binding DNA with reasonable affinity.74 Although
DNA binding is a logical candidate in terms of the responsibility
for the antimicrobial activity of the polypyridylruthenium(II) com-
plexes, Lam et al. recently demonstrated that a bis(2,20-bipyridine)-
ruthenium(II) complex containing a N-phenyl-substituted
diazafluorene ligand significantly increased the production of
reactive oxygen species in MRSA.75 The authors suggested that
the good activity observed against MRSA (6.25 mg ml1) could be
due to DNA damage caused by the reactive oxygen species.
The antimicrobial activity of polypyridylruthenium(II) complexes
upon photo-activation has also been investigated. Another complex,
[Ru(dmob)3]Cl2 (dmob = 4,40-dimethoxy-2,2 0-bipyridine, Fig. 4f)
exhibited good antimicrobial activity upon irradiation of light
(MIC = 12.5 mg ml1 against S. aureus) and demonstrated consider-
able promise as a photosensitiser for use in photodynamic anti-
microbial chemotherapy.76
Fig. 4 Mononuclear polypyridylruthenium(II) complexes exhibiting antimicrobial activity. (a) [Ru(phen)3]
2+; (b) [Ru(Me4phen)3]
2+; (c) [Ru(Me4phen)2(acac)]
+;
(d) [Ru(2,9-Me2phen)2(dppz)]
2+; (e) [Ru(bpy)3]
2+; (f) [Ru(dmob)3]
2+.
Review Article Chem Soc Rev
This journal is©The Royal Society of Chemistry 2015 Chem. Soc. Rev., 2015, 44, 2529--2542 | 2535
The development of the mononuclear polypyridylruthenium(II)
complexes as antimicrobial agents was limited due to their com-
paratively high MIC values compared with antibacterials currently
in clinical use; however, their potential against drug-resistant
bacterial strains is still promising. Although the mode of action
of these ruthenium complexes is not well understood, DNA binding
is normally considered the major interaction leading to the anti-
microbial activity. Consequently, dinuclear and higher nuclearity
complexes with relatively larger size, higher charge and nucleic acid
binding affinity were expected to be better candidates as antimi-
crobial agents.
4.1.1.2 Dinuclear and oligonuclear complexes. Until very
recently, few dinuclear or oligonuclear polypyridylruthenium(II)
complexes have been studied for their antimicrobial activities.
Most of the dinuclear complexes were designed and developed to
improve their DNA binding properties compared to the corres-
ponding mononuclear complexes. A selection of the commonly
used bridging ligands is shown in Fig. 5.
Aldrich-Wright and co-workers investigated the intercalative
dinuclear complex [{Ru(dpq)2}2(m-phen-x-SOS-x-phen)]
4+ (dpq =
dipyrido[3,2-d:2030-f]quinoxaline; SOS = 2-mercaptoethyl ether; x =
3, 4 or 5) and found the complex had a DNA binding affinity of
6 107 M1, a significant improvement upon the mononuclear
analogues [Ru(dpq)2(phen)]
2+ (K = 5.4  104 M1), [Ru(dpq)2-
(phen-4-SOS)]2+ (K = 2.3  106 M1), or [Ru(bpy)2(dpq)]2+ (K =
5.9  104 M1).77,78 Ruthenium complexes containing dppz and
tpphz ligands (see Fig. 5) have also been reported to display very
high affinity to duplex or quadruplex DNA by intercalation, with
low salt concentration dependence.79–83 Lincoln and co-workers
developed a bis-intercalating dinuclear complex, DD-[m-c4-
(cpdppz)2-(phen)4Ru2]
4+ (cpdppz = 12-cyano-12,13-dihydro-
11H-cyclopenta[b]dipyrido-[3,2-a:20,30-c]phenazine-12-carbonyl),
that bound DNA with extremely high affinity and very slow
dissociation kinetics.79,80,82 Additionally, Thomas and co-workers
found a series of dinuclear ruthenium complexes containing
tpphz bound quadruplex DNA with high affinity, even at high
ionic strengths, and exhibited a blue-shifted light-switch
effect.83 The beneficial effect of multi-nuclearity on DNA affi-
nity was also well illustrated by the groove-binding dinuclear
complexes [{Ru(bpy)2}2(m-bbn)]
4+ (n = 3 or 5) first investigated by
Kelly and co-workers.84,85 Comparison of the dinuclear species
with mononuclear analogues revealed that the dimetallic
complexes had much higher DNA-binding affinities, were more
efficient at photosensitising DNA strand breaks, and were less
sensitive to ionic strength.84,85 Furthermore Keene, Collins
and co-workers used bpm and HAT-bridged species to probe
the non-duplex DNA selectivity of bulky dinuclear metal com-
plexes. However, the dinuclear complexes bridged by a rigid
planar ligand cannot follow the curvature of the minor groove
unless the groove is significantly straightened by bulge-induced
bending.86,87 Consequently, these workers investigated the
non-duplex DNA binding of a series of complexes [{Ru(phen)2}2-
(m-bbn)]
4+ (where n = 2, 5, 7, 10, 12 or 16, see Fig. 6), based upon
the flexibly-bridged [{Ru(bpy)2}2(m-bbn)]
4+ species described
by Kelly et al. In addition, Keene and co-workers resolved
the three stereoisomeric forms of the [{Ru(bpy)2}2(m-bbn)]
4+
species, and examined their binding affinity to a number of
different oligonucleotide sequences and structures using a
variety of techniques.88
Fig. 5 Common di-bidentate bridging ligands for dinuclear complexes: (a) 2,20-bipyrimidine [bpm], (b) 1,4,5,8,9,12-hexaazatriphenylene [HAT], (c) 4,6-
bis(2-pyridyl)pyrimidine [dppm], (d) 2,3-bis(2-pyridyl)benzo[g]quinoxaline [dpb], (e) 2,3-bis(2-pyridyl)pyrazine [2,3-dpp], (f) 3-pyrazin-2-yl)as-triazino-
[5,6-f ]-1,10-phenanthroline [pztp], (g) tetrapyrido[3,2-a:20,30-c:300,200-h:2 0 0 0,30 0 0-j]phenazine [tpphz], (h) bis[4(40-methyl-2,2 0-bipyridyl)]-1,n-alkane [bbn]
(i) 2,9-bis(2-imidazo[4,5-f][1,10]phenanthroline-1,10-phenanthroline [bipp], (j) 11,110-bis(dipyrido[3,2-a:20,30-c]phenazine [dppz(11,11 0)dppz], (k) 1,10-
phenanthroline-5-(2 mercaptoethyl ether)-5-1,10-phenanthroline [SOS].
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Given their DNA binding ability, the potential of the Rubbn class
of complexes as novel antimicrobial agents was subsequently
examined. The Rubbn complexes were highly active against a range
of pathogenic bacteria, particularly Gram positive strains, e.g. see
Table 3.89 In addition, preliminary toxicity experiments indicated
the ruthenium complexes were significantly less toxic to eukaryotic
cells (see Table 3).89 Furthermore, the Rubbn maintained their
activity against drug-resistant bacteria, including strains that are
of considerable current concern, e.g. MRSA and VRE. The Rubbn
complexes with a longer alkane linking chain (Rubb12, Rubb14 and
Rubb16) were the most active.
89 Interestingly, the dinuclear com-
plexes with a short linking chain (bb2 and bb5), a rigid polycyclic
aromatic linking ligand (bpm and dppm) or those containing an
ether or amine in the linking ligand, showed very little or no activity
against any of the bacterial strains.89 Only slight differences in
activity were observed between the DD and LL enantiomers.
Cellular uptake studies provided a rationale for the observed
relative differences in activity for the ruthenium complexes.90
Rubb16 exhibited the highest level of cellular uptake, followed by
Rubb12 and then Rubb7, consistent with the trend in lipophilicity of
the dinuclear complexes (logP = 1.9, 2.7 and 3.4 for Rubb16,
Rubb12 and Rubb7, respectively).
90 However, this correlation was
not observed for the mononuclear complexes [Ru(phen)2(bb7)]
2+
and [Ru(Me4phen)3]
2+. Consistent with the observed MIC/MBC
(MBC = minimum bactericidal concentration) values for each
ruthenium complex the uptake into Gram negative bacteria was
significantly less than that into Gram positive species.90
Furthermore, it was shown that the dinuclear Rubbn complexes
enter bacterial cells in an energy-independent manner, and
significantly depolarise and permeabilise the cellular membrane.91
Interestingly, while [Ru(Me4phen)3]
2+ also depolarised the
bacterial cells, there was no sign of membrane permeabilisation,
again indicating a significant difference in the biological processing
of this complex and the dinuclear complexes.91 It was proposed
that [Ru(Me4phen)3]
2+ has a different mode of cellular entry and/or
different intracellular target compared to the dinuclear ruthenium
complexes. Although the Rubbn complexes can permeabilise
membranes, cellular localisation studies also showed that the most
active compound Rubb16 preferentially binds RNA in live bacteria,
accumulating at ribosomes and condensing the ribosomes when
they existed as polysomes (see Fig. 7).92 The specific targeting and
condensation of polysomes would halt translation, thereby inter-
rupting protein synthesis in actively growing bacterial cells.
Consistent with the importance of lipophilicity and cellular
uptake, a dinuclear ruthenium helicate complex based upon the
bidentate ligand pyridyl-1,2,3-triazole – which has the same cationic
charge as the Rubbn complexes but is less lipophilic – showed
extremely modest antimicrobial activity.93 The authors postulated
that the lack of activity was probably due to poor intracellular
uptake, and proposed that increasing the hydrophobicity of the
ruthenium helicate could lead to better antimicrobial activity.
Given the good antimicrobial activity exhibited by the dinuc-
lear Rubbn complexes, the antimicrobial activities of the corres-
ponding tri- and tetra-nuclear complexes (see Fig. 8) were also
examined.94 Additionally, due to the modular nature of the
synthesis of these complexes, it was possible to synthesise both
linear and non-linear tetranuclear complexes. All the tri- and
tetra-nuclear complexes exhibited good antimicrobial activity,
with the linear Rubb12-tri, Rubb16-tri, Rubb12-tetra and Rubb16-
tetra the most active compounds – up to four-times more active
than the dinuclear counterparts. While the trinuclear complexes
were the most lipophilic based upon logP values, the linear
tetranuclear complexes were generally more active. Interestingly,
although the non-linear tetranuclear complexes were slightly
more lipophilic they were consistently less active than their
linear counterparts.94 Although the level of cellular accumula-
tion of the tri- and tetra-nuclear complexes in Gram negative
bacteria was equal to or greater than in Gram positive species,
considerably lower activity was observed against the Gram
negative species. This suggested that some Gram negative species,
Fig. 6 The structure of the dinuclear polypyridylruthenium(II) complexes
Rubbn, where n = 2, 5, 7, 10, 12, 14 or 16.
Table 3 MIC, HC50
a and IC50 values of four dinuclear Rubbn complexes
(DD-Rubb7, DD-Rubb10, DD-Rubb12 and DD-Rubb16) against S. aureus,
E. coli, red blood cells and THP-1b cells. The data was taken from ref. 89
Bacteria Eukaryotic cells
S. aureus E. coli Red blood THP-1
Ruthenium
complex
MIC
[mg ml1]
MIC
[mg ml1]
HC50
[mg ml1]
IC50
[mg ml1]
DD-Rubb7 16 16 41024 400
DD-Rubb10 4 4 410 300
DD-Rubb12 1 2 160 135
DD-Rubb16 1 4 22 78
a HC50: concentration needed to induce 50% haemolysis.
b THP-1 cells
are a human monocytic leukemia cell line and a good model for
nucleated eukaryotic cells.
Fig. 7 Left-hand side: fluorescence microscopy image of Rubb16 localisation
in E. coli at 4 mg ml1, showing condensation of polysomes. Scale bar = 5 mm.
Right-hand side: Rubb16 localisation with the image re-processed to enhance
the luminescence of the Rubb16 bound to all ribosomes. Adapted from ref. 92.
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particularly P. aeruginosa, have inherent resistance to inert
polypyridyl ruthenium complexes.
4.1.2. Localisation of inert ruthenium complexes in eukaryotic
cells. For a compound to be a clinically useful antimicrobial or
anticancer drug, it must be highly active against bacteria (or
cancer cells) but exhibit low toxicity towards humans or animals.
While the toxicity of a new compound can only be determined
through in vivo studies, an understanding of the mechanism(s)
of toxicity can be gained through the study of the biological
processing of the compound in isolated eukaryotic cells. As
a consequence, there has been considerable recent interest
in the localisation of ruthenium complexes in a variety of
human and animal cells. Due to their strong luminescent
properties, the intracellular localisation of polypyridyl-
ruthenium complexes can be readily examined by confocal micro-
scopy. Several excellent reviews on the cellular uptake and
localisation of polypyridylruthenium complexes have been
previously published.58,95
Considerable diversity in the cellular localisation of mono-
nuclear complexes has been observed, even within the same
basic structure. For example, Lincoln and Norde´n have
reported the remarkable cellular control by the length of an
alkyl chain in a dppz-based complex (dppz = dipyrido[3,2-
a:20,30-c]phenazine) – the least lipophilic species (those with
the shortest alkyl chains) were found to stain nuclear DNA; the
most lipophilic complexes preferably stained cellular mem-
branes, whereas those derivatives of [Ru(phen)2(dppz)]
2+ of
intermediate lipophilicity selectively stained the RNA-rich
nucleoli.62 Given that lipophilicity appears to play an important
role in cellular localisation, appending various moieties to a
ruthenium complex could modify the localisation site – and
hence the biological activity of the metal complex. For example,
Fig. 8 The structure of the tri- (Rubbn-tri) and tetra-nuclear (Rubbn-tetra) polypyridylruthenium(II) complexes.
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Puckett and Barton have demonstrated that conjugating an
octaarginine moiety to a dppz complex of ruthenium increased
its cellular and nuclear uptake.96 However, while the cellular
uptake significantly increased, for incubation at 5 mM complete
exclusion from the nucleus was observed. It was concluded that
the uptake mechanism had been altered by the addition of the
arginine peptide – passive diffusion to endocytosis – with the
ruthenium conjugate being trapped in endosomes. Interest-
ingly, addition of fluorescein to the ruthenium–octaarginine
complex redirected the conjugate to the nucleus, with nuclear
fluorescence and strong nucleoli staining observed.96
In an important early study with dinuclear complexes, Onfelt
et al. demonstrated that the ruthenium complex DD-[m-c4-
(cpdppz)2-(phen)4Ru2]
4+ can be used as a nuclear stain in live
cells, although electroporation of the V79 Chinese hamster cells
was required for the ruthenium complex to bind nuclear DNA.82
The DNA imaging potential of another dinuclear polypyridyl-
ruthenium(II) complex has been demonstrated by Thomas and
co-workers – [{Ru(phen)2}2(tpphz)]
4+ (see Fig. 9).58,61 Interestingly,
the more lipophilic complex 4,7-diphenyl-1,10-phenanthroline
analogue [{Ru(DIP)2}2(m-tpphz)]
4+ localised in the endoplasmic
reticulum.97 More recently, Thomas and co-workers reported a
study of the cellular uptake and localisation of iridium(III)–
ruthenium(II) dinuclear complexes bridged by the tpphz ligand.98
The water soluble cyclometalated complexes [Ir(ppy)2(tpphz)Ru-
(bpy)2]
3+ and [Ir(F2ppy)2(tpphz)Ru(bpy)2]
3+ {ppy = 2-phenyl-pyridine
and F2ppy = 2-(4-fluorophenyl)pyridine} were rapidly internalised
in HeLa cells and localised in the nucleus. This study is particularly
significant in that nuclear localisation wasmaintained even though
the [Ir(III)–Ru(II)]3+ complexes are more lipophilic (and hence
possess superior uptake) than the corresponding [Ru(II)–Ru(II)]4+
complexes. As noted by the authors,98 generally the addition of
hydrophobic groups to improve cellular uptake leads to localisation
in hydrophobic regions (e.g. membrane structures) rather than in
the nucleus – as observed for [{Ru(DIP)2}2(m-tpphz)]
4+.97
By contrast, the [{Ru(phen)2}2(m-bbn)]
4+ dinuclear complexes
were predominantly taken up by passive diffusion through the
cell membrane in L1210 murine leukaemia cells, with a minor
contribution from an active structure-specific, non-endocytotic
mechanism.99 Confocal microscopy was used to show that the
complexes with n = 12, 14 and 16 accumulated exclusively in the
mitochondria.99 However, a study of the intracellular localisation
of the [{Ru(phen)2}2(m-bbn)]
4+ complexes with organ (liver and
kidney) cells lines showed a high degree of selectivity for the
nucleus of the eukaryotic cells (see Fig. 10).100 Additional
co-localisation experiments with SYTO 9, a general nucleic
acid stain, indicated that the ruthenium complexes showed a
considerable preference for the RNA-rich nucleolus. However,
while the ruthenium complexes exhibited a preference for the
nucleoli, significant general DNA binding within the nucleus was
also observed when the ruthenium complex was incubated at
50 mM. No significant differences were observed in the intracellular
localisation between the DD and LL enantiomers of the dinuclear
Fig. 9 The structure of [(Ru(phen)2)2(tpphz)]
4+ (a); and (b) the nuclear DNA
staining of the dinuclear complex in MCF-7 cells, as evident by the red
luminescence, with co-staining by the general nucleic acid stain SYTO-9 shown
in green (highlighting the nucleoli). Adapted with permission from ref. 58.
Fig. 10 Rubb12 localisation in BHK cells at 10 mM, stained by DAPI (blue),
SYTO 9 (light blue), DD-Rubb12 (red) and merged (bottom right), where white
is co-localisation of SYTO 9 and DD-Rubb12 and magenta is co-localisation of
DAPI and DD-Rubb12. Scale bar = 10 mm. Adapted from ref. 100.
Table 4 24 hour-IC50 values (mM) against the BHK, HEK-293 and Hep-G2 cell
lines, and the minimum inhibitory concentration (MIC; mM) against S. aureus
and E. coli for the ruthenium complexes. The data was taken from ref. 100a
BHK HEK-293 Hep-G2 S. aureus E. coli
Rubb12 70.5 50.9 61.7 0.6 2.5
Rubb12-tetra 27.7 21.7 33.8 0.3 1.2
a BHK = baby hamster kidney, HEK-93 = human embryonic kidney and
Hep-G2 = liver carcinoma.
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complex. Interestingly, despite targeting the RNA-rich regions in
both bacteria (ribosomes) and organ cells (nucleoli), the Rubbn
complexes do exhibit a considerable degree of selective toxicity
towards bacteria.100 As shown in Table 4, Rubb12 and Rubb12-tetra
are significantly more toxic to the Gram positive bacterium
S. aureus and the Gram negative species E. coli compared to three
eukaryotic cell lines when assayed over similar time frames.
4.2 Ruthenium complexes with labile ligands
Ruthenium complexes were initially developed as lower toxic
alternatives to the platinum anticancer complexes. The activities of
amminechloridoruthenium(III) complexes, such as cis-[RuCl2-
(NH3)4]Cl, trans-[RuCl4(Im)2](HIm) (Im = imidazole), and fac-[RuCl3-
(NH3)3] were explored initially and this class of complexes showed
good anticancer activity.101 In vivo studies with tumour-bearing
animals demonstrated that trans-[RuCl4(Im)2](HIm) exhibited good
activity against platinum-resistant colorectal tumours. Another
class of ruthenium complexes with labile ligands, based on
chloridodimethylsulfoxideruthenium(II), were shown to be signifi-
cantly less toxic than the platinum complexes;101 the dimethylsulf-
oxide ligands of these complexes improved their selectivity towards
tumour metastases, although they also reduced their activity. The
most successful examples of ruthenium complexes with labile
ligands as anticancer agents are imidazolium trans-imidazoledi-
methysulfoxidetetrachloridoruthenate (NAMI-A) and indazolium
bis-indazoletetrachloridoruthenate (KP1019) (see Fig. 3e, f), which
have entered clinical trials.102 Interestingly, although in general the
anticancer activity of metal complexes is due to their DNA binding
property, NAMI-A acts as an inhibitor of the metastatic potential of
tumours and the activity is not related with DNA binding.101
A family of Schiff base ruthenium(III) complexes, [RuX(Z3-
Schiff)(Eph3)2] (Eph3 = triphenylphosphine/arsine, X = Cl or Br),
containing labile ligands showed better antibacterial activity than
their parent ligands against B. subtilis and E. coli.103 However,
only moderate inhibition was observed using the disc diffusion
method at relatively high concentrations. The antimicrobial
activity of a series of ruthenium complexes with PTA (1,3,5-
triaza-7-phosphaadamantane) ligands and various labile ligands
(Cl, Br, I or SCN) were also tested. The complexes with Cl
or SCN exhibited antifungal activity while those with Br or I
were found to be inactive.104,105 More encouragingly, chiral
ruthenium(II) salen complexes containing DMSO ligands
showed good activity (MIC = 12 to 25 mg ml1) against Gram
positive bacteria, but were inactive against Gram negative
species.106 Interestingly, the S enantiomer exhibited better
activity than the R enantiomer. In another approach, Kamatchi
et al. synthesised several organometallic ruthenium(II) complexes
[Ru(HL)(CH3CN)(CO)(EPh3)2] (where HL = 4-oxo-4H-pyran-2,6-
dicarboxylic acid and E = As or P) and examined their anti-
microbial activity.107 However, while the ruthenium complexes
were more active than their parent ligands, they only exhibited
moderate activity (MICZ 25 mg ml1) against a range of bacteria.
A series of dinuclear polypyridylruthenium(II) complexes
containing labile chlorido ligands, [{Ru(tpy)Cl}2(m-bbn)]
2+ {Cl–
Rubbn; where tpy = 2,20:60,200-terpyridine and bbn = bis[4(40-
methyl-2,20-bipyridyl)]-1,n-alkane – see Fig. 11} was examined
for antimicrobial activity.108 These labile dinuclear complexes
showed good activity, with MIC values for the Cl–Rubb12 complex
of 1 mg ml1 against two Gram positive bacteria (including MRSA)
and 2 and 8 mg ml1 against several Gram negative species.108
Interestingly, the toxicity of the Cl–Rubbn complexes to bacteria
increased with increasing methylene groups in the linking ligand
up to n = 12, but then decreased for the Cl–Rubb16 complex. It
was proposed that, compared to the corresponding inert complexes
[{Ru(phen)2}2(m-bbn)]
4+ (Rubbn), the inclusion of the chlorido group
on each metal centre increased the cellular uptake but decreased
the ability of the ruthenium complexes to kill bacteria.108
5. Conclusions and future
perspectives
It is clear that new antimicrobial agents are needed, but
paradoxically, there are fewer drugs in the development ‘‘pipeline’’
than a decade ago. Although research into new organic-based
antimicrobial agents continues, there is now growing interest
in metal-based drugs. Due to the shifting of interest away from
platinum towards ruthenium for the development of novel
anticancer compounds, there is now also considerable focus
developing on ruthenium(II) complexes as antimicrobial agents.
In general, ruthenium(II) complexes have shown good activity
towards Gram positive bacteria (e.g. S. aureus and MRSA),
but lower activity to Gram negative species (e.g. E. coli and
P. aeruginosa). As would be expected, the antimicrobial activity
of a ruthenium complex is a function of lipophilicity, charge
and charge separation. However, for an antimicrobial to have
clinical potential it must also be relatively non-toxic to humans
and animals. Simply increasing lipophilicity and charge
simultaneously is likely to produce ruthenium complexes
that are more active in both bacteria and eukaryotic cells. Given
the modular design and general ease with which the structure
of the ruthenium complexes can be modified, the aim now
becomes preparing new ruthenium complexes that exhibit high
levels of selective toxicity towards bacteria.
While polycations would generally be toxic to cells, differences
in the membrane composition between bacteria and eukaryotic
cells can provide a degree of selectivity. Ruthenium complexes
could selectively target bacterial cells due to the greater presence
of negatively-charged components (phospholipids, such as
phosphatidyl-glycerol, teichoic acids and lipopolysaccharides)
Fig. 11 Structure of chlorido-containing dinuclear metal complexes
Cl–Rubbn (M = Ru, b = 2). Iridium analogues Cl–Irbbn (M = Ir, b = 4) were
also prepared and exhibited good antimicrobial activity.108
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in the bacterial membrane and cell wall.109 In contrast, the
high content of zwitterionic phosphatidylcholine in the outer
membrane leaflet of healthy eukaryotic cells confers an overall
neutral charge on these cells that results in a greatly reduced
capacity for electrostatic interactions. However, and more
generally, the relative hydrophilicity and high charge of some of
the ruthenium complexes would suggest that the metal complex
could not freely diffuse across the bacterial membrane. Hence,
there is a need to understand the interaction of the ruthenium
complexes with lipid bilayers. Liposomes are a good model
for biological membranes and have been extensively used to
study drug interactions with phospholipid bilayers,110 and
there are a variety of well established procedures to examine
the interactions, e.g. inductively-coupled plasma spectroscopy,
differential scanning calorimetry and NMR spectroscopy.110
DNA binding is generally suggested or implied as the possible
intra-cellular target for ruthenium complexes, particularly inert
polypyridyl species, with significant antimicrobial activity.
However, toxicity is a major concern for the DNA-targeting metal
complexes. Due to the lack of variation in the structure of DNA
between bacteria and eukaryotic cells, DNA is unlikely to provide
the selectivity required for development of a clinically-useful
antimicrobial drug. RNA is more structurally rich than DNA:
RNA contains a larger proportion of non-duplex type structures,
forming complex three-dimensional structures comprising of
loops, bulges, pseudo knots and turns. In addition, viral and
bacterial RNA often have ‘unusual’ sequences and folds that could
be specifically targeted.111 Consequently, RNA may provide a
better target than DNA for the development of new ruthenium-
based antimicrobials. In support of this notion, studies have
demonstrated that a variety of mono- and di-nuclear polypyridyl-
ruthenium complexes preferentially target RNA over DNA, localis-
ing in nucleoli in eukaryotic cells and ribosomes in bacteria.
Ribosomes are a particularly attractive target for ruthenium
complexes, given the significant differences between eukaryotic
and bacterial ribosomes. As noted earlier, a variety of organic-
based drugs target bacterial ribosomes.
While a variety of ruthenium complexes have demonstrated
good in vitro antimicrobial activity, and in some cases significantly
less toxicity to eukaryotic cells,63,89,100 the clinical potential is
related to the in vivo activity. Before an in vivo study using mice
infected by bacteria can be carried out, it is necessary to
determine the toxicity of the ruthenium complexes. Pharmaco-
kinetic studies, where the concentration of the metal complex
in serum and various organs are determined as a function of
time after administration, are also required. However, once an
understanding of pharmacokinetics is obtained, it is likely that
ruthenium(II) complexes can be designed that have selective
toxicity for bacteria and good residence time in human serum
after administration. As previously noted, the lipophilicity,
charge and charge separation can be relatively easily controlled;
and due to the rigid octahedral geometry of the ruthenium
complexes, optimising binding affinity at cellular target sites
may be easier than for purely organic-based drugs. Further-
more, it seems more likely that a completely new mechanism of
antimicrobial activity will be obtained with a ruthenium(II)
complex, compared to organic molecules which have been
the major class of compounds studied since the development
of penicillin.112
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